Budget Impact Analysis of Using Pazopanib-Everolimus in First and Second Line of Treatment, In Patients with Metastatic Renal Cell Carcinoma
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2135
https://www.valueinhealthjournal.com/article/S1098-3015(16)33501-X/fulltext
Title :
Budget Impact Analysis of Using Pazopanib-Everolimus in First and Second Line of Treatment, In Patients with Metastatic Renal Cell Carcinoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33501-X&doi=10.1016/j.jval.2016.09.2135
First page :
A719
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2025